© 2026 Sinochem Nanjing Corporation,
All Right Reserved
|
HS Code |
282859 |
As an accredited 4-Bromomethypiperidine-1-Carboxylic Acid Tert-Butyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 4-Bromomethypiperidine-1-Carboxylic Acid Tert-Butyl Ester prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Organic synthesis keeps evolving, with chemists narrowing their sights on intermediary compounds that streamline complex builds. Among the tools that have shaped medicinal and materials chemistry, 4-Bromomethylpiperidine-1-Carboxylic Acid Tert-Butyl Ester stands out. Chemists like myself remember the frustration of working with reactive intermediates prone to side reactions or limited adaptability. The tert-butyl ester derivative presents a smoother route, offering both the stability and selectivity essential for intricate molecular designs. Its role extends across the production of pharmaceuticals, advanced polymers, and chemical probes.
With the molecular formula C11H20BrNO2, this compound draws attention because of two features. The bromomethyl group attached to the piperidine ring acts as a handy anchor for forming carbon–carbon or carbon–heteroatom bonds. The presence of the tert-butyl ester on the carboxyl group provides a stable, removable protecting group that withstands harsh conditions yet allows for straightforward hydrolysis when the time is right. Chemists who have struggled with premature deprotection in acid-sensitive settings immediately recognize the value here, especially when setting up multistep processes that demand both resilience and flexibility.
Bromomethyl groups rarely get the appreciation they deserve. Their halogenated nature means they are ready to react with nucleophiles, such as amines and thiols, allowing for a clean, direct route to a wide variety of next-step products. For researchers mapping out CNS-active compounds or complex natural products, the ability to precisely place new functionalities without excessive byproducts pays off in shorter timelines and less purification headache. In the world of linker chemistry, this molecule often serves as the essential bridge connecting bioactive units with drug carriers or imaging tags.
Many intermediates in pharmaceutical R&D look promising on paper but break down when faced with scale-up, storage, or real-world reaction conditions. What grabbed my attention about the tert-butyl ester-protected piperidine derivative was its staying power. During routine chromatography or storage under atmospheric conditions, it doesn't degrade or lose its protecting groups. The molecule stays in form for months, resisting hydrolysis and oxidation much better than unprotected analogs. In pilot plants, where batches run into the kilogram scale, this stability translates into reliable yields and less time troubleshooting reactors clogged with side products.
Every medicinal chemist has a set of favorite building blocks, and derivatives of piperidine frequently top that list. The 4-bromomethyl derivative, specifically with a tert-butyl protected acid, earns its keep in developing kinase inhibitors, GPCR ligands, and enzyme-targeted probes. In design projects, the piperidine ring often acts as a scaffold imparting solubility and bioavailability, while the bromine atom opens up streamlined routes for Suzuki or Buchwald couplings. I’ve seen teams use this intermediate to introduce diverse side chains for SAR (structure–activity relationship) studies, bridging the gap between high-throughput parallel synthesis and scalable preparation for animal testing.
The market offers a full spectrum of piperidine-based intermediates, including unprotected acids, methyl, and phenyl derivatives. Still, not all serve the same roles. Free acids require special handling and often limit the conditions usable downstream, especially during acid-catalyzed manipulations. Methyl derivatives don’t bring the leaving-group flexibility that bromomethyl provides, restricting the paths for further derivatization. Even compared with nitro- or chloro-substituted siblings, this bromomethyl ester strikes the right balance of leaving-group ability and manageable reactivity. The tert-butyl group, compared with benzyl or ethyl esters, resists most unwanted transformations, saving time during deprotection, especially under mild acidic conditions that leave other sensitive groups unscathed.
Safety and practicality often dictate choices in the synthetic lab. Brominated intermediates sometimes raise eyebrows for their handling requirements, but the tert-butyl ester’s bulky nature cuts down volatility and offers a powder or crystalline solid that manages well in glass or polyethylene containers. My own experience with a well-sealed, dry environment keeps batches stable for over a year, with no need for refrigeration or inert atmosphere. No need to dread unexpected decomposition or evaporation — as long as the cap stays on and humidity stays low, the compound keeps its integrity.
Synthetic organic chemistry thrives on options. This compound supports a wide array of transformations, from nucleophilic displacement of the bromomethyl group to stepwise ester cleavage. Researchers often use it to anchor PEG chains for targeted delivery, or to link fluorescent tags for bioimaging. Many peptides and small-molecule inhibitors built on piperidine frameworks benefit from the flexibility to fine-tune polarity, steric bulk, and linker length at early or late stages. I’ve relied on its reactivity in everything from straightforward alkylations to custom modifications in bioconjugate projects, with the confidence that product isolation won’t turn into a weeklong ordeal.
Even with the best intermediates, reactions can run off-script. Anecdotes echo across research groups: unprotected acid versions sometimes migrate during silica purification; poorly protected amines tend to give mixed products. In contrast, the tert-butyl-protected acid generally comes through cleanly. Bromomethyl’s leaving-group power streamlines substitution reactions under mild conditions, reducing the temperature and time needed compared to bromoalkanes lacking electronic stabilization from the neighboring nitrogen and ester. For those trying to build new carbon–carbon or carbon–nitrogen bonds in medicinal chemistry, a reproducible conversion rate means less batch-to-batch variation. I’ve seen teams shave days off project timelines by switching to tert-butyl-protected routes that sidestep persistent byproducts.
The presence of bromine brings up familiar concerns around waste and process safety. Having handled multiple brominated intermediates across academic and process labs, I know the best practice involves thorough containment and neutralization of waste streams. The tert-butyl group limits volatility, minimizing the risk of airborne contamination compared to lighter alkyl esters or bromides. Modern waste protocols recover bromine and neutralize it efficiently, and most research labs train team members in appropriate containment. Awareness remains key, but for teams following standard chemical hygiene, this intermediate rates among the more manageable options.
The route to reliable final products kicks off with unambiguous compound identity and high purity. In hands-on workups, clear analytical signals for the bromomethyl, tert-butyl, and piperidine moieties make NMR and mass spectrometry straightforward. LC-MS usually shows a clean parent ion and minimal fragmentation. Research groups working in regulated environments, such as contract manufacturing or clinical batch preparation, appreciate that lots reach 97–99% purity without extensive purification. Well-designed processes sidestep persistent impurities that plague other piperidine derivatives, such as dibromides or hydrolysis products. Tight batch-to-batch consistency means scale-up doesn’t introduce uncertainty at the pilot plant or production line.
Drug discovery cycles move quickly now — much faster than in decades past. This intermediate fits into diverse reaction schemes, boosting efficiency for both exploratory and scale-driven synthesis. Lead optimization projects using this tert-butyl ester can quickly access libraries for target screening or early bioassays. Analytical teams find that samples traveling between synthetic, purification, and biology labs maintain their integrity, supporting more predictable timelines from bench to animal studies. Companies aiming for first-in-human studies appreciate intermediates that translate smoothly between milligram and kilogram runs, cutting down transfer and troubleshooting times that typically drag out preclinical phases.
Contract (custom) manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) play pivotal roles in the pharmaceutical supply chain, turning lab breakthroughs into scalable products. Their needs revolve around robust intermediates that carry through multiple steps without skipping a beat. This tert-butyl-protected, bromomethyl-piperidine derivative ticks the right boxes for both early-stage route scouting and late-stage production transfer. The compound holds up well under varying storage parameters, reducing cost and risk for CMOs held responsible for inventory at scale. Clients seeking reliable batch reproducibility tend to favor compounds exhibiting this sort of chemical resilience.
One regular worry for industrial chemists involves hidden costs embedded in synthesis, such as costly reagents, excessive solvent use, or energy-hungry workups. Here, the tert-butyl group can be cleaved under mild conditions, using common acids like trifluoroacetic. Paired with the efficient substitution reactions enabled by bromomethyl, these features allow for minimized side-reactions and clean product isolation, pushing process metrics in the right direction. As more chemical companies publish sustainability reports, the demand for intermediates enabling high atom economy and straightforward waste disposal keeps growing. Shifting from legacy intermediates with dated protecting groups to this improved design often speaks for itself in project budgets and environmental impact statements.
Over the years, numerous academic groups have published new reaction protocols using 4-Bromomethylpiperidine-1-Carboxylic Acid Tert-Butyl Ester as a key building block. Some have explored new palladium-catalyzed cross-couplings to elaborate drug candidates, others have built molecular probes for receptor mapping. Industrial labs focus on streamlining routes, converting base piperidine structures to advanced analogues using less solvent and fewer hazardous reagents — the bromomethyl ester frequently proves the shortest route from idea to bench test. Colleagues from process chemistry teams report greater lot-to-lot reproducibility, and fewer out-of-spec issues during scaleup, especially compared with unprotected or unhalogenated versions.
Patenting new drugs and technologies often hinges on the ability to access protected intermediates that don’t infringe on existing claims. The structure of this tert-butyl ester, featuring both a bromomethyl handle and a robust ester, opens up diverse chemical real estate. Teams building new assets, from small-molecule drugs to functionalized polymers, report that starting from this protected piperidine leads to patentable derivatives that leapfrog common competitive structures. This advantage plays a real role in securing freedom to operate and maximizing exclusivity windows, a reality that resonates with anyone navigating the final stages of IND-enabling campaigns.
Complex target molecules — pharmacophores, labelled agents, sensor platforms — call for intermediates that don’t throw curveballs. In the world of modular synthesis, this tert-butyl ester with a bromomethyl group supports orthogonal strategies, allowing for selective transformations at both the nitrogen and carboxyl positions. Peptide chemists link on the bromomethyl for side-chain extension, while materials scientists attach new functionalities via the tert-butyl-protected acid group. The ability to direct reactivity as needed streamlines design cycles, a fact I’ve often leveraged in troubleshooting difficult convergent synthesis projects.
Route scouting in early drug discovery often comes down to testing variants quickly, with an eye on what can survive intense conditions without falling apart. The stability of the tert-butyl group, paired with the chemically versatile bromomethyl position, means chemists can explore radical and ionic chemistries without risking the core of the molecule. For teams developing routes to new kinase inhibitors or antivirals, this ability to “fail fast” and optimize quickly means reaching tractable, scalable processes sooner. In my experience, replacing legacy intermediates with this molecule in established routes eliminated slow, expensive side reactions and boosted overall project ROI.
While I see many strengths in using this intermediate, no compound comes without its caveats. Bromine-derived leaving groups, if not fully converted, may linger as trace impurities and need diligent monitoring during downstream reactions. Sensitive assays also call for complete removal of tert-butyl cleaving reagents and careful workup to avoid contamination. Process teams should remain aware of the potential for minor hydrolysis under extended acidic conditions, especially during high-temperature processing. These small hurdles can be managed through proper analytical monitoring and incremental optimization — experience on the bench shows that solid workup routines usually catch these minor pitfalls.
As the chemical sciences push deeper into precision synthesis, the appetite for modular, reliable intermediates continues to expand. The design behind 4-Bromomethylpiperidine-1-Carboxylic Acid Tert-Butyl Ester primes it for next-generation medicinal chemistry, targeted delivery systems, and expanded roles in applied materials. Researchers in academia and industry are developing new ligands, linkers, and bioconjugates that benefit from the versatility and performance of this molecule. Anticipating regulatory expectations and sustainability pressures, efforts are also underway to further streamline production at scale, minimize waste streams, and extend the shelf life of this and related intermediates.
Every working chemist recognizes the pain of failed reactions and chasing purity through long days. Having reliable, flexible intermediates like this bromomethyl piperidine ester means fewer setbacks. It gives scientific teams confidence — less chasing unexpected contaminants, more headway toward project milestones. I’ve seen projects halt over minor stability issues with unprotected acids or unwieldy leaving groups, stretching budgets and patience. Compounds that cut down on these persistent hurdles earn lasting respect in the lab, building a quiet but powerful case for adoption and routine use in both academic and manufacturing environments.
Selecting building blocks shapes the direction and speed of every synthesis. Beyond purity and regulatory status, decisions rest on versatility, proven performance, and support for robust process control. This tert-butyl-protected derivative stands out as a solid choice for advanced intermediates, serving innovators from medicinal chemistry groups to industrial process chemists. Feedback from dozens of hands-on projects keeps reinforcing its value in practical terms — low waste, stable handling, predictable reactivity, and a direct path from bench-top experimentation to large-scale delivery.
